每经AI快讯，博雅生物（SZ 300294，收盘价：22.77元）12月16日晚间发布公告称，截至本公告日，高 特佳集团累计质押股数约为3687万股，占其所持股份比例为64.63%。融华投资累计质押股数为95万 股，占其所持股份比例为67.84%。 截至发稿，博雅生物市值为115亿元。 每经头条（nbdtoutiao）——中标企业频频弃标 大型医疗设备采购有何难言之隐？ （记者 曾健辉） 2025年1至6月份，博雅生物的营业收入构成为：血液制品业务占比84.58%，生化类药物占比8.63%，复 大医药经销业务占比6.12%，其他行业占比0.65%，其他业务占比0.02%。 ...

截至发稿，博雅生物市值为120亿元。 每经头条（nbdtoutiao）——国开行辟谣的"人民资产"是什么？记者实探：号称投资600元80天赚8万 元！一位投资人的女儿：劝不住她，警察都拦不住 （记者 胡玲） 每经AI快讯，博雅生物（SZ 300294，收盘价：23.85元）11月26日晚间发布公告称，公司第八届第十七 次董事会会议于2025年11月26日在公司会议室以现场加通讯表决的方式召开。会议审议了《关于增补第 八届董事会独立董事的议案》等文件。 2025年1至6月份，博雅生物的营业收入构成为：血液制品业务占比84.58%，生化类药物占比8.63%，复 大医药经销业务占比6.12%，其他行业占比0.65%，其他业务占比0.02%。 ...

Group 1 - The core point of the article is that Boya Bio (SZ 300294) announced that as of the announcement date, Gaotejia Group has pledged approximately 37.32 million shares, accounting for 65.42% of its holdings [1] - As of the report, Boya Bio's market capitalization is 12.8 billion yuan [1] - For the first half of 2025, Boya Bio's revenue composition is as follows: blood products account for 84.58%, biochemical drugs account for 8.63%, pharmaceutical distribution accounts for 6.12%, other industries account for 0.65%, and other businesses account for 0.02% [1]

Group 1 - The core point of the article is that Boya Bio (SZ 300294) held its 16th meeting of the 8th Board of Directors on October 27, 2025, to review the performance contracts for the management team for the year 2025 [1] - For the first half of 2025, Boya Bio's revenue composition is as follows: blood products account for 84.58%, biochemical drugs for 8.63%, pharmaceutical distribution for 6.12%, other industries for 0.65%, and other businesses for 0.02% [1] - As of the report date, Boya Bio has a market capitalization of 12.4 billion yuan [1]